DBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, raised $93 million by offering 4.3 million ADSs at $21.64, below its $23 proposed offer price. DBV Technologies will list on the NASDAQ under the symbol DBVT. The Bagneux, France-based company is currently listed on the Euronext Paris under the symbol DBV. Citi, Leerink Partners and Bryan, Garnier & Co acted as joint bookrunners on the deal.
